 cord
ischemia, and other complications that are associated with
open repair can also occur with TEVAR.
Although there is no device currently commercially
available with an on-label indication for repair of traumatic thoracic aortic transections, these are increasingly
being treated off-label using endovascular devices. At the
time of this manuscript, there were at least two ongoing
investigator device exemption (IDE) pivotal clinical trials in187

JOURNAL OF VASCULAR SUR